Ipsen (WBO:IPN) Receipts from Customers

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:IPN Ipsen SA WBO:IPN
93 GF Score
Price €161.50
GF Value €142.86
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Ipsen Receipts from Customers?

Receipts from Customers only applicable to companies reporting Cash Flow from Operations in direct method.

WBO:IPN
93GF Score
Ipsen SA WBO:IPN
Receipts from Customers is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ipsen (WBO:IPN) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €161.50 is trading 13% above its estimated GF Value™ of €142.86. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for WBO:IPN:

  • Receipts from Customers:
  • GF Value™: €142.86 vs. price of €161.50 (13% above fair value)
  • GF Score™: 93/100 with 6 warning signs

No single metric tells the full story. See the WBO:IPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
93GF Score

Get the complete analysis for WBO:IPN

Receipts from Customers is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€161.50
Price
€142.86
GF Value